CY2021036I2 - Αντισωματα anti-angptl3 και χρησεις αυτων - Google Patents

Αντισωματα anti-angptl3 και χρησεις αυτων

Info

Publication number
CY2021036I2
CY2021036I2 CY2021036C CY2021036C CY2021036I2 CY 2021036 I2 CY2021036 I2 CY 2021036I2 CY 2021036 C CY2021036 C CY 2021036C CY 2021036 C CY2021036 C CY 2021036C CY 2021036 I2 CY2021036 I2 CY 2021036I2
Authority
CY
Cyprus
Prior art keywords
angptl3 antibodies
angptl3
antibodies
Prior art date
Application number
CY2021036C
Other languages
English (en)
Other versions
CY2021036I1 (el
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46298728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2021036(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY2021036I1 publication Critical patent/CY2021036I1/el
Publication of CY2021036I2 publication Critical patent/CY2021036I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CY2021036C 2011-06-17 2021-12-06 Αντισωματα anti-angptl3 και χρησεις αυτων CY2021036I2 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498518P 2011-06-17 2011-06-17
US201161578309P 2011-12-21 2011-12-21

Publications (2)

Publication Number Publication Date
CY2021036I1 CY2021036I1 (el) 2022-03-24
CY2021036I2 true CY2021036I2 (el) 2022-05-27

Family

ID=46298728

Family Applications (2)

Application Number Title Priority Date Filing Date
CY181101324T CY1120996T1 (el) 2011-06-17 2018-12-11 Αντισωματα anti-angptl3 και χρησεις αυτων
CY2021036C CY2021036I2 (el) 2011-06-17 2021-12-06 Αντισωματα anti-angptl3 και χρησεις αυτων

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY181101324T CY1120996T1 (el) 2011-06-17 2018-12-11 Αντισωματα anti-angptl3 και χρησεις αυτων

Country Status (46)

Country Link
US (7) US9018356B2 (el)
EP (2) EP2721065B1 (el)
JP (2) JP6400471B2 (el)
KR (1) KR102031007B1 (el)
CN (1) CN103732624B (el)
AR (1) AR087329A1 (el)
AU (1) AU2012271663B2 (el)
CA (1) CA2838867C (el)
CL (1) CL2013003552A1 (el)
CO (1) CO6821892A2 (el)
CR (1) CR20130621A (el)
CY (2) CY1120996T1 (el)
DK (1) DK2721065T3 (el)
DO (1) DOP2013000299A (el)
EC (1) ECSP13013085A (el)
ES (1) ES2699499T3 (el)
FI (1) FIC20210028I1 (el)
FR (1) FR21C1061I2 (el)
GT (1) GT201300306A (el)
HR (1) HRP20182098T1 (el)
HU (1) HUS2100034I1 (el)
IL (2) IL229612B (el)
JO (1) JO3412B1 (el)
LT (2) LT2721065T (el)
LU (1) LUC00231I2 (el)
MA (1) MA35190B1 (el)
MX (2) MX337644B (el)
MY (1) MY160516A (el)
NI (1) NI201300136A (el)
NL (1) NL301122I2 (el)
NO (2) NO2021037I1 (el)
PE (1) PE20141166A1 (el)
PH (1) PH12013502570B1 (el)
PL (1) PL2721065T3 (el)
PT (1) PT2721065T (el)
RS (1) RS58310B1 (el)
RU (1) RU2620064C2 (el)
SG (1) SG195165A1 (el)
SI (1) SI2721065T1 (el)
SM (1) SMT201800658T1 (el)
TR (1) TR201816591T4 (el)
TW (3) TW201920261A (el)
UA (1) UA114891C2 (el)
UY (2) UY34137A (el)
WO (1) WO2012174178A1 (el)
ZA (1) ZA201308879B (el)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087329A1 (es) * 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
WO2017011929A1 (zh) * 2015-07-17 2017-01-26 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
EP3416684B1 (en) * 2016-02-17 2023-06-21 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3
EA201891979A1 (ru) * 2016-03-03 2019-01-31 Ридженерон Фармасьютикалз, Инк. Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3
KR20180132843A (ko) 2016-04-08 2018-12-12 리제너론 파아마슈티컬스, 인크. Angptl8 억제제 및 angptl3 억제제로 고지혈증을 치료하는 방법
CA3021884A1 (en) * 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methods for treating patients with familial hypercholesterolemia
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
MX382035B (es) 2016-11-17 2025-03-13 Regeneron Pharma Uso de un inhibidor angptl8 en la preparación de un medicamento para tratar la obesidad.
KR102659791B1 (ko) 2017-07-06 2024-04-23 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
WO2019126194A1 (en) 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
CN111479618B (zh) 2017-12-22 2022-08-02 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
MX2020008095A (es) 2018-01-31 2020-09-24 Regeneron Pharma Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos.
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
KR20200127979A (ko) 2018-02-28 2020-11-11 리제너론 파마슈티칼스 인코포레이티드 바이러스 오염물질을 확인하기 위한 시스템 및 방법
KR102503356B1 (ko) 2018-03-19 2023-02-24 리제너론 파마슈티칼스 인코포레이티드 마이크로칩 모세관 전기영동 분석 및 시약
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
AU2019329686A1 (en) 2018-08-27 2020-12-03 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
US11754569B2 (en) 2018-08-30 2023-09-12 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
CN113396158A (zh) * 2018-11-26 2021-09-14 诺华股份有限公司 Lpl-gpihbp1融合多肽
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
CN117110492A (zh) 2019-01-16 2023-11-24 瑞泽恩制药公司 鉴别蛋白质中的游离巯基的方法
US20220144961A1 (en) * 2019-03-11 2022-05-12 Xyence Therapeutics, Inc. Cd27-binding antibodies and uses thereof
US20200363400A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Competitive Ligand Binding Assays
US20200369760A1 (en) * 2019-05-24 2020-11-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-angptl3 antibodies
CN112062845B (zh) * 2019-06-10 2022-09-02 山东博安生物技术股份有限公司 Angptl3结合片段及其用途
MX2022000094A (es) * 2019-07-04 2022-04-27 Cadila Healthcare Ltd Vacuna a base de angptl3 para el tratamiento de enfermedad hepática.
IL317159A (en) 2019-09-24 2025-01-01 Regeneron Pharma Systems and methods for use in chromatography and regeneration
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
AU2020394428A1 (en) 2019-11-25 2022-07-14 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
CN110938144B (zh) * 2019-11-27 2022-07-26 复旦大学附属儿科医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
CA3165060C (en) 2020-01-21 2023-06-20 Yiming Zhao Deglycosylation methods for electrophoresis of glycosylated proteins
US20230138315A1 (en) * 2020-01-22 2023-05-04 Jiangsu Hengrui Medicine Co., Ltd. Anti-angptl3 antibody and use thereof
TW202225398A (zh) 2020-08-31 2022-07-01 美商再生元醫藥公司 用以改良細胞培養效能及減少天冬醯胺序列變異之天冬醯胺饋料策略
MX2023006077A (es) 2020-11-25 2023-06-06 Regeneron Pharma Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.
JP2024500409A (ja) 2020-12-17 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質封入マイクロゲルの作製
TW202233827A (zh) 2021-01-20 2022-09-01 美商再生元醫藥公司 改良細胞培養中蛋白質效價的方法
IL305156A (en) 2021-03-03 2023-10-01 Regeneron Pharma Systems and methods for quantifying and modifying protein viscosity
WO2022187353A1 (en) * 2021-03-05 2022-09-09 Anji Pharmaceuticals Inc. Methods and compositions for treating sepsis
IL305731A (en) 2021-03-26 2023-11-01 Regeneron Pharma Methods and systems for developing mixing protocols
WO2022205021A1 (zh) * 2021-03-30 2022-10-06 复旦大学附属儿科医院 一种抗angptl3抗体或其抗原结合片段及其制备方法和用途
KR20240015646A (ko) 2021-06-01 2024-02-05 리제너론 파마슈티칼스 인코포레이티드 마이크로칩 모세관 전기영동 분석 및 시약
WO2023001228A1 (zh) * 2021-07-21 2023-01-26 江苏恒瑞医药股份有限公司 一种抗angptl3抗体或其抗原结合片段的药物组合物及其用途
US20230077710A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
WO2023044139A1 (en) 2021-09-20 2023-03-23 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
CN118076894A (zh) 2021-10-07 2024-05-24 里珍纳龙药品有限公司 pH建模和控制的系统及方法
CA3230985A1 (en) 2021-10-07 2023-04-13 Ross BROWNE Ph meter calibration and correction
EP4423018A1 (en) 2021-10-26 2024-09-04 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
CN116284377A (zh) * 2021-12-21 2023-06-23 复旦大学 抗人血管生成素3纳米抗体及其应用
MX2024007900A (es) * 2021-12-22 2024-07-10 Regeneron Pharma Tratamiento de enfermedades renales con inhibidores de la angiopoyetina tipo 3 (angptl3).
EP4493921A1 (en) 2022-03-18 2025-01-22 Regeneron Pharmaceuticals, Inc. Methods and systems for analyzing polypeptide variants
AU2023264772A1 (en) * 2022-05-02 2024-10-24 Novo Nordisk A/S Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
CN117603361A (zh) * 2022-08-22 2024-02-27 复旦大学附属儿科医院 包含angptl3单抗的融合蛋白
CN116143919B (zh) * 2022-11-01 2025-06-13 中国药科大学 全人源抗人nt-angptl3抗体、其抗原结合片段及其应用
WO2024130165A1 (en) 2022-12-16 2024-06-20 Regeneron Pharmaceuticals, Inc. Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome
EP4634659A1 (en) 2022-12-16 2025-10-22 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
TW202445135A (zh) 2023-01-25 2024-11-16 美商再生元醫藥公司 液態蛋白質組成物穩定性之建模方法
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
WO2024178213A2 (en) 2023-02-22 2024-08-29 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
TW202508625A (zh) 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品
CN119192369A (zh) * 2023-06-25 2024-12-27 百奥泰生物制药股份有限公司 抗angptl3抗体及其应用
TW202528736A (zh) 2023-09-08 2025-07-16 美商再生元醫藥公司 用於評估層析管柱完整性的方法及系統
US20250095773A1 (en) 2023-09-18 2025-03-20 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
WO2025072597A2 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
CN117535353A (zh) * 2023-10-11 2024-02-09 首都医科大学附属北京潞河医院 一种糖尿病视网膜病变模型的建立方法及应用
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
WO2025096932A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020035058A1 (en) 1996-05-15 2002-03-21 The University Of Sheffield Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
WO2002067901A1 (en) 2001-02-22 2002-09-06 Skyepharma Canada Inc. Fibrate-statin combinations with reduced fed-fasted effects
CN1615440A (zh) 2001-11-16 2005-05-11 杰南技术公司 含有血管生成素－样蛋白质3angptl3的组合物及其使用方法
JP2006517785A (ja) 2002-10-29 2006-08-03 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
JP2005080508A (ja) 2003-09-04 2005-03-31 Sankyo Co Ltd 脂質代謝改善剤の試験方法
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
CA2601677A1 (en) 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP1962895B2 (en) 2005-12-16 2016-01-20 Regeneron Pharmaceuticals, Inc. THERAPEUTIC USE OF A Dll4 ANTAGONIST AND A VEGF INHIBITOR FOR INHIBITING TUMOR GROWTH
CN102585002A (zh) 2006-06-02 2012-07-18 瑞泽恩制药公司 人il-6受体的高亲和力抗体
EP2069403B1 (en) * 2006-10-02 2014-05-07 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
EP2121751B1 (en) 2006-12-08 2017-01-25 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against angptl3
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
EP2216016A1 (en) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising ezetimibe
CN101852805B (zh) 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
PT2453921E (pt) 2009-07-14 2015-09-25 Novartis Ag Diferenciação de células estaminais mesenquimais
ES2677969T3 (es) 2010-01-08 2018-08-07 Ionis Pharmaceuticals, Inc. Modulación de la expresión tipo angiopoyetina 3
AR087329A1 (es) * 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
KR102554896B1 (ko) * 2011-06-21 2023-07-12 알닐람 파마슈티칼스 인코포레이티드 안지오포이에틴-유사 3(ANGPTL3) iRNA 조성물 및 그 사용 방법
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
EP3770259A1 (en) 2013-12-24 2021-01-27 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
BR112016024850B1 (pt) 2014-05-01 2021-07-06 Ionis Pharmaceuticals, Inc compostos e composições para modulação da expressão de angptl3 e seus usos
CA2955294A1 (en) 2014-07-16 2016-01-21 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
EP3416684B1 (en) 2016-02-17 2023-06-21 Regeneron Pharmaceuticals, Inc. Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3
EA201891979A1 (ru) 2016-03-03 2019-01-31 Ридженерон Фармасьютикалз, Инк. Способы лечения пациентов с гиперлипидемией введением ингибитора pcsk9 в комбинации с ингибитором angptl3
KR20180132843A (ko) 2016-04-08 2018-12-12 리제너론 파아마슈티컬스, 인크. Angptl8 억제제 및 angptl3 억제제로 고지혈증을 치료하는 방법
CA3021884A1 (en) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Methods for treating patients with familial hypercholesterolemia
US20200369760A1 (en) * 2019-05-24 2020-11-26 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-angptl3 antibodies

Also Published As

Publication number Publication date
GT201300306A (es) 2015-03-09
FIC20210028I1 (fi) 2021-09-09
ZA201308879B (en) 2014-07-30
PL2721065T3 (pl) 2019-02-28
MX361859B (es) 2018-12-18
LTC2721065I2 (el) 2022-10-25
IL259436A (en) 2018-07-31
LT2721065T (lt) 2018-12-10
MX2013014345A (es) 2014-01-31
NL301122I1 (el) 2021-09-01
PH12013502570B1 (en) 2019-01-16
UY39340A (es) 2021-08-31
CN103732624A (zh) 2014-04-16
HUS2100034I1 (hu) 2021-10-28
JP6400471B2 (ja) 2018-10-03
NI201300136A (es) 2014-05-15
CY2021036I1 (el) 2022-03-24
ES2699499T3 (es) 2019-02-11
SI2721065T1 (sl) 2018-12-31
SG195165A1 (en) 2013-12-30
CL2013003552A1 (es) 2014-07-25
AR087329A1 (es) 2014-03-19
LUC00231I2 (el) 2025-02-03
CA2838867C (en) 2020-07-14
US9018356B2 (en) 2015-04-28
MY160516A (en) 2017-03-15
US20150197564A1 (en) 2015-07-16
CR20130621A (es) 2014-02-12
UA114891C2 (uk) 2017-08-28
JP2014523739A (ja) 2014-09-18
US20250136675A1 (en) 2025-05-01
KR20140037218A (ko) 2014-03-26
CN103732624B (zh) 2016-08-17
SMT201800658T1 (it) 2019-01-11
RU2620064C2 (ru) 2017-05-22
LTPA2021009I1 (el) 2021-09-27
FR21C1061I2 (fr) 2022-11-18
EP3418301A1 (en) 2018-12-26
PT2721065T (pt) 2018-12-06
AU2012271663B2 (en) 2017-04-20
US9951127B2 (en) 2018-04-24
NO2021037I1 (no) 2021-09-15
CA2838867A1 (en) 2012-12-20
ECSP13013085A (es) 2014-01-31
IL229612B (en) 2019-06-30
DK2721065T3 (en) 2018-12-03
TW201815822A (zh) 2018-05-01
WO2012174178A1 (en) 2012-12-20
RU2013155906A (ru) 2015-07-27
US20220403016A1 (en) 2022-12-22
TWI644922B (zh) 2018-12-21
MX337644B (es) 2016-03-14
CO6821892A2 (es) 2013-12-31
MA35190B1 (fr) 2014-06-02
US20130171149A1 (en) 2013-07-04
TW201313738A (zh) 2013-04-01
CY1120996T1 (el) 2019-12-11
JP2018166516A (ja) 2018-11-01
EP2721065B1 (en) 2018-09-12
NO2025028I1 (no) 2025-06-13
DOP2013000299A (es) 2014-04-15
PE20141166A1 (es) 2014-09-16
US20220153825A1 (en) 2022-05-19
TR201816591T4 (tr) 2018-11-21
UY34137A (es) 2013-01-03
PH12013502570A1 (en) 2014-01-27
AU2012271663A1 (en) 2014-01-16
NZ619092A (en) 2016-03-31
IL229612A0 (en) 2014-01-30
EP2721065A1 (en) 2014-04-23
JO3412B1 (ar) 2019-10-20
US20190315851A1 (en) 2019-10-17
NL301122I2 (nl) 2021-12-30
TW201920261A (zh) 2019-06-01
KR102031007B1 (ko) 2019-11-08
RS58310B1 (sr) 2019-03-29
US20190092845A1 (en) 2019-03-28
US10358487B2 (en) 2019-07-23
HRP20182098T1 (hr) 2019-02-08
FR21C1061I1 (fr) 2022-01-21

Similar Documents

Publication Publication Date Title
CY2021036I2 (el) Αντισωματα anti-angptl3 και χρησεις αυτων
CY2020045I2 (el) Anti-pd-l1 αντισωματα και χρησεις αυτων
HUS2300021I1 (hu) Anti-IL-36R antitestek
CY2022019I2 (el) Συνθεσεις αντι-cgrp και χρησεις αυτων
CY2024022I2 (el) Αντιμυκητιασικοι παραγοντες και χρησεις αυτων
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
IL231777B (en) Antibodies against tl1a and uses thereof
IL249650A0 (en) Antibodies directed against icos and uses thereof
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
CO6811812A2 (es) Anticuerpo anti-b7-h3
BR112012030311A2 (pt) anticorpo
LT2794654T (lt) Anti-phf-tau antikūnai ir jų panaudojimas
CO7071096A2 (es) Anticuerpos anti-lgr5 e inmunoconjugados
EP2714735A4 (en) SPECIFIC ANTIBODIES OF TGF BETA
DK3381943T3 (da) Anti-kit-antistoffer og anvendelser deraf
BR112015002193A2 (pt) anticorpos anti-etbr e imunoconjugados
CR20140127A (es) Anticuerpo anti-abtcr
BR112014009050A2 (pt) pirrolbenzodiazepinas e conjugados destas
HUE056313T2 (hu) Anti-DLL3 antitest
DK2668210T3 (da) Anti-kit antistoffer og anvendelser deraf
DK2683406T3 (da) Anti-cd40-antistoffer og anvendelser deraf
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
BR112014025037A2 (pt) anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
CO6791565A2 (es) Anticuerpos anti-notch1
DK3453723T3 (da) Anti-ASIC1-antistoffer og anvendelser deraf